Part 1 of this article, published in last month’s
issue, began an exploration of the introduction of highly active retroviral
therapy (HAART) and its dramatic impact on the morbidity and mortality of people
infected with the human immunodeficiency virus. The discussion focused mainly on
the acquired immunodeficiency syndrome (AIDS)-related malignancies Kaposi’s
sarcoma (KS) and non-Hodgkin’s lymphoma (NHL). Part 2 will conclude with an
examination of the impact of HAART on primary central nervous system lymphoma (PCNSL),
primary effusion lymphoma (PEL), cervical cancer and dysplasia, and the non-AIDS-defining
malignancies Hodgkin’s lymphoma and anogenital neoplasia.
Approximately 1% of individuals with AIDS develop primary central nervous
system lymphoma.[1,2] PCNSL usually occurs in advanced stages of immune
dysfunction, typically with CD4 counts below 50 cells/µL.[2,3] Presumably,
the impact of immune reconstitution observed with HAART would be most apparent
in malignancies typically associated with severe immunosuppression. The effect
of HAART on the incidence and clinical course of CNS lymphoma is not yet clear.
PCNSL in human immunodeficiency virus (HIV)-infected patients is uniformly
associated with Epstein-Barr virus.[4-6] The pathogenesis is unclear, but may
involve cellular transformation by Epstein-Barr virus gene products, including
Epstein-Barr virus latent membrane protein (LMP-1). Transformation results in
overexpression of bcl-2, a protein that has been demonstrated to inhibit
Patients with PCNSL usually present with confusion, memory loss, and
lethargy.[2,3,7] Focal neurologic defectsincluding hemiparesis, aphasia,
seizures, cranial nerve palsies, and headacheare not uncommon. The
majority of patients have multifocal lesions on radiographic imaging.[1,8] Most
PCNSLs display a B-cell phenotype and diffuse large cell or immunoblastic
The prognosis for individuals with HIV-PCNSL is very poor. If untreated,
median survival ranges from 4 to 8 weeks.[3,9] Radiation therapy may prolong
survival, but is used primarily as palliative treatment. Historically, the
majority of patients who complete adequate radiotherapy (3,000 to 5,400 cGy) die
from intercurrent opportunistic infections.[9,10]
In PCNSL occurring in seronegative individuals, the use of chemotherapy alone
or with radiation has transformed a once fatal disease into a potentially
curable disease. Prior to the use of high-dose methotrexate, the median survival
for HIV-negative individuals with PCNSL was 14 months, with only 3% to 26% of
individuals surviving 5 years. Early data suggest that the use of high-dose
methotrexate, alone or in combination with radiotherapy, in non-HIV-related
PCNSL results in complete response rates of 65% and 2-year survival rates of
Until recently, cytotoxic therapies effective in treating PCNSL, such as
high-dose methotrexate, have not been feasible in the profoundly
immunocompromised patients that typify this population. Jacomet and colleagues
treated 15 individuals with HIV-PCNSL with high-dose methotrexate (3 g/m² every
14 days × 6 cycles). This patient population had a mean CD4 count of 30
cells/mL and a median Karnofsky performance status of 50. The complete response
rate was 50% with a median survival of 10 months. It is likely that the ability
to deliver adequate cytotoxic therapy to patients with HIV-PCNSL may
dramatically improve outcomes in the HAART era.
Impact of HAART
Demonstration of a decrease in the incidence of PCNSL in HIV-infected
individuals since the introduction of HAART is difficult given the small number
of cases. While several smaller studies have failed to demonstrate a significant
decrease in the incidence of PCNSL, two of the largest published studies
indicate a significant decline (Table 1).
The impact of HAART on treatment outcomes of HIV-PCNSL is likely to be
significant. At present, limited data exist, but anecdotal reports are
promising. At the very least, the improved immune function and decreased
incidence of opportunistic infections afforded by HAART may improve outcomes of
patients treated with radiotherapy. In addition, aggressive treatment of HIV-PCNSL
with systemic chemotherapy may become a realistic goal.
Interestingly, direct effects of HAART on PCNSL have been reported. Corales
and colleagues described two patients treated with HAART alone for HIV-PCNSL.
Both patients had dramatic clinical responses and were alive at 8 and
21 months from the time of diagnosis. HAART regimens varied and were not
selected based on CNS penetration.
Freiberg and colleagues recently presented data demonstrating a possible role
for hydroxyurea in the treatment of HIV-PCNSL. Hydroxyurea has previously
been shown to induce loss of Epstein-Barr virus episomes from lymphoblastoid-
and Burkitt’s lymphoma-derived cell lines. The investigators described two
patients with PCNSL who were treated with low-dose hydroxyurea (400 to 700
mg/m²/d) and HAART. Despite minimal improvement in CD4 count and viral load,
both patients showed dramatic improvement clinically and radiographically, with
survivals of 23 to 25 months. The authors concluded that the observed responses
were primarily due to Epstein-Barr virus-targeted therapy with hydroxyurea,
given the lack of demonstrated immune reconstitution with HAART.
Further investigations exploring the use of antiviral therapy are under way.
Previously, Raez and colleagues demonstrated a 43% complete response rate in
seven patients with HIV-PCNSL treated with intravenous zidovudine (Retrovir),
ganciclovir (Cytovene), and interleukin (IL)-2.[3,15] In vitro data have shown
that some B cell lymphoma cell lines undergo apoptosis after exposure to
zidovudine and ganciclovir. As a result of these observations, the AIDS
Malignancy Consortium is planning a phase II study investigating the use of
induction intravenous zidovudine, ganciclovir, and IL-2 followed by maintenance
subcutaneous IL-2 and oral ganciclovir in patients with HIV-PCNSL. All patients
will be treated with HAART for the duration of the study.
Primary effusion lymphoma (PEL), also called body cavity-based lymphoma, is
an aggressive non-Hodgkin’s lymphoma found primarily in HIV-infected
individuals. PEL accounts for 1% to 5% of all AIDS-related NHL. Clinically,
PEL presents as malignant effusions in patients with advanced AIDS.[17,18] The
usual nodal and extranodal solid tumors associated with sytemic HIV-NHL are
notably absent in patients with PEL. High-grade immunoblastic morphology is
characteristic. Immunohistochemistry reveals a null phenotype, devoid of
typical B- and T-cell markers.[17,18] The presence of human herpesvirus-8
(HHV-8) can be demonstrated in all HIV-related PELs, and clonal Epstein-Barr
virus is frequently, though not universally, found.[4,18,19] Men who report a
history of sex with men are disproportionately affected by PEL. Up to 50% of
patients have a prior history of Kaposi’s sarcoma.[18,20]
The pathogenesis of PEL is not clear, but the strong association with HHV-8
is suggestive of a viral role in lymphomagenesis. HIV-related PELs express
several HHV-8 encoded gene products that affect B-cell growth, including vIL-6
and viral cyclin.[4,18] Antibodies targeting the IL-6 signaling pathway have
inhibited clonal growth of AIDS-PEL in vitro and in an animal model. Given
the significant percentage of PELs that demonstrate coinfection with
Epstein-Barr virus and HHV-8, a possible second-hit model of lymphomagenesis is
The prognosis for HIV-infected individuals with PEL is grim, with
a median survival of only 3 to 5 months. Many patients are critically
ill at the time of diagnosis, making systemic chemotherapy difficult to
administer. Historically, most patients who are treated receive combination
chemotherapy regimens used in other aggressive HIV-related lymphomas. No
standard therapy currently exists for this rare lymphoma.
Impact of HAART
Given the rarity of PEL, it is not surprising that few data exist regarding
the impact of HAART. Emerging data suggest that antiviral therapy may be
effective in PEL.
Recently, Boulanger and colleagues presented retrospective data involving a
series of 12 patients with HIV-related PEL. Eight of the patients died from 3
weeks to 8 months after diagnosis. Three had prolonged survivals with a
variety of treatment strategies, including interferon-alfa plus cidofovir
(Vistide) in one, high-dose chemotherapy in one, and initiation of HAART in the
Additionally, Berryman presented a case report of a patient with advanced
AIDS and aggressive PEL who was treated with lamivudine (Epivir), stavudine
(Zerit), abacavir, and nelfinavir (Viracept). The patient achieved a
complete remission within 6 weeks and was alive without evidence of lymphoma
after 8 months of follow-up.
As the roles of HHV-8 and Epstein-Barr virus in the development of PEL are
elucidated, pathogenic-based therapy will continue to be developed. Currently,
the initiation of HAART appears to be an important component of the therapeutic
1. Deangelis L: Current management of primary central nervous system
lymphoma. Oncology 9:63-78, 1995.
2. Gill PS, Levine AM, Meyer RP, et al: Primary central nervous system
lymphoma in homosexual men: Clinical, immunologic and pathologic features. Am J
Med 78:742-748, 1985.
3. Levine AM: Acquired immunodeficiency syndrome-related lymphoma: Clinical
aspects. Semin Oncol 27:442-453, 2000.
4. Gaidano G, Capello D, Carbone A: The molecular basis of acquired
immunodeficiency syndrome-related lymphomagenesis. Semin Oncol 27:431-441, 2000.
5. Kaplan LD: HIV-associated lymphoma. AIDS Clin Rev 98:349-373, 1997.
6. MacMahon EME, Glass JD, Hayward SD, et al: Epstein-Barr virus in
AIDS-related primary central nervous system lymphoma. Lancet 338:969-963, 1991.
7. DeMario MD, Liebowitz DN: Lymphomas in the immunocompromised patient.
Semin Oncol 25:492-502, 1998.
8. Antinori A, Ammassari A, De Luca A, et al: Diagnosis of AIDS-related focal
brain lesions: A decision-making analysis based on clinical and neuroradiologic
characteristics combined with polymerase chain reaction assays in csf. Neurology
9. Baumgartner J, Rachlin J, Beckstead J, et al: Natural history and response
to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J
Neurosurg 73:206-211, 1990.
10. Goldstein JD, Dickson DW, Moser FG, et al: Primary central nervous system
lymphoma in acquired immune deficiency syndrome. Cancer 67:2756-2765, 1991.
11. Ferreri AJM, Reni M, Villa E: Therapeutic management of primary central
nervous system lymphoma: Lessons from prospective trials. Ann Oncol 11:927-937,
12. Jacomet C, Girard PM, Lebrette MG, et al: Intravenous methotrexate for
primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS
13. Corales R, Taege A, Rehm S, et al: Regression of AIDS-related CNS
lymphoma with HAART. Program and abstracts of the XIII International AIDS
Conference (abstract MoPpB1086). Durban, South Africa, July 9-14, 2000.
14. Freiberg AS, Slobod KS, Taylor GH, et al: EBV-targeted therapy for
AIDS-related primary central nervous system lymphoma (abstract 596). 42nd Annual
American Society of Hematology Meeting, San Francisco, December 2000.
15. Raez L, Cabral L, Cai JB, et al: Antivirals induce apoptosis and tumor
regression in AIDS related primary central nervous system lymphoma. Third AIDS
Malignancy Conference, Bethesda, Md, 1999. J Acquir Immune Defic Syndr 21:A31,
16. Baiocchi RA, Peng R, Schmalbrock P, et al: An in vivo preclinical model
to evaluate an effective antiviral regimen in Epstein-Barr virus-associated
primary central nervous system lymphoma (abstract). International Conference on
Malignant Lymphoma, Lugano, Switzerland, June 2-5, 1999.
17. Cannon M, Cesarman E: Kaposi’s sarcoma-associated herpesvirus and
acquired immunodeficiency syndrome-related malignancy. Semin Oncol 27:409-419,
18. Komanduri K, Luce JA, McGrath MS, et al: The natural history and
molecular heterogeneity of HIV-associated primary malignant lymphomatous
effusions. J Acquir Immune Defic Syndr 13:215-226, 1996.
19. Cesarman E, Chang Y, Moore PS, et al: Kaposi’s sarcoma-associated
hepesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N
Engl J Med 332:1186-1191, 1995.
20. Boulanger E, Agbalika F, Maarek O, et al: A clinical, molecular and
cytogenic study of 12 cases of human herpesvirus 8 associated primary effusion
lymphoma (abstract 4683). Presented at the 42nd Annual American Society of
Hematology Meeting, San Francisco, December 2000.
21. Burger R, Bakker F, Baum W, et al: In primary effusion lymphoma, HHV-8
derived IL-6 is important (abstract 1456). Presented at the 42nd Annual American
Society of Hematology Meeting, San Francisco, December 2000.
22. Berryman RB: Primary effusion lymphomaComplete remission with HAART
(abstract 4741). Presented at the 42nd Annual American Society of Hematology
Meeting, San Francisco, December 2000.
23. Biggar RJ, Rabkin CS: The epidemiology of AIDS-related neoplasms. Hematol
Oncol Clin North Am 10(5):997-1010, 1996.
24. Goedert J: Epidemiology of acquired immune deficiency syndrome
malignancies. Semin Oncol 27:390-401, 2000.
25. Maiman M, Fruchter RG, Guy L, et al: Human immunodeficiency virus
infection and invasive cervical carcinoma. Cancer 71:402-406, 1993.
26. Goedert JJ, Cote TR, Virgo P, et al: Spectrum of AIDS-associated
malignant disorders. Lancet 351:1833-1839, 1998.
27. Biggar R: Cancers in AIDS: What types and what clues to etiology? 2nd
National AIDS Malignancy Conference, Bethesda, Md,
28. Maiman M, Tarricone N, Viera J, et al: Colposcopic evaluation of human
immunodeficiency virus-positive women. Obstet Gynecol 78:84-88, 1991.
29. Frisch M, Goedert JJ, Biggar RJ: Human papillomavirus-associated
anogenital cancers in patients with HIV infection and AIDS (abstract S5).
Abstracts of the 4th International AIDS Malignancy Conference, Bethesda, Md, May
16-18, 2000. J Acquir Immune Defic Syndr 23:A9, 2000.
30. Berry J, Palefsky J: Pathogenesis and clinical manifestations of
HIV-associated anogenital neoplasia. AIDS Knowledge Base, November 1998, http://hivinsite.ucsf.edu
31. Robinson W: Invasive and preinvasive cervical neoplasia in human
immunodeficiency virus-infected women. Semin Oncol 27:463-470, 2000.
32. Maiman M: Management of cervical neoplasia in human immunodeficiency
virus-infected women. J Natl Cancer Inst Monogr 23:43-49, 1998.
33. Wright TC, Koulos J, Schnoll F, et al: Cervical intraepithelial neoplasia
in women infected with the human immunodeficiency virus: Outcomes after LOOP
electrosurgical excision. Gynecol Oncol 55:253-258, 1994.
34. Fruchter RG, Maiman M, Sedlis A, et al: Multiple recurrences of cervical
intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet
Gynecol 87:338-344, 1996.
35. Maiman M, Fruchter RG, Serur E, et al: Human immunodeficiency virus
infection and cervical neoplasia. Gynecol Oncol 38(3):377-382, 1990.
36. Fruchter RG, Maiman M, Arrastia CD, et al: Is HIV infection a risk factor
for advanced cervical cancer? J Acquir Immune Defic Syndr Hum Retrovirol
37. Beral V, Peterman TA, Berkelman RL, et al: Kaposi’s sarcoma among
persons with AIDS: A sexually transmitted infection. Lancet 335:123-128, 1990.
38. Delmas MC, Agarossi A, Bergeron C, et al, Incidence of squamous
intraepithelial lesions (SIL) in HIV-infected women (abstract 623/22306). Int
Conf AIDS 12:324, 1998.
39. Heard I, Schmitz V, Costagliola D, et al: Early regression of cervical
lesions in HIV-seropositive women receiving highly active antiretroviral
therapy. AIDS 12:1459-1464, 1998.
40. Centers for Disease Control and Prevention: 1997 USPHS/IDSA guidelines
for the prevention of opportunistic infections in persons infected with human
immunodeficiency virus. Morbid Mortal Weekly Rep 46:1-46, 1997.
41. Maiman M, Watts DH, Andersen J, et al: Vaginal 5-fluorouracil for
high-grade cervical dysplasia in human immunodeficiency virus infection: A
randomized trial. Obstet Gynecol 94(6):954-961, 1999.
42. Trubowitz P, Gates A, Kaplan L: Non-AIDS-defining malignancies, in HIV
and HTLV-1 Malignancies, pp 303-328. Kluwer Academic, Dordrecht, 2001.
43. Hessol NA, Katz MH, Liu JY, et al: Increased incidence of Hodgkin’s
disease in homosexual men with HIV infection. Ann Intern Med 117:309-311, 1992.
44. Spina M, Vaccher E, Nasti G, et al: Human immunodeficiency
virus-associated Hodgkin’s disease. Semin Oncol 27:480-488, 2000.
45. Biggar RJ, Frisch M, Engels EA, et al: The National AIDS-Cancer Match
Registry. Abstracts of the 4th International AIDS Malignancy Conference,
Bethesda, Md, May 16-18, 2000 (abstract S3). J Acquir Immune Defic Syndr 23:A8,
46. Rubio R: Hodgkin’s disease associated with human immunodeficiency virus
infection: A clinical study of 46 cases. Cancer 73:2400-2407, 1994.
47. Tirelli U, Errante D, Dolcetti R, et al: Hodgkin’s disease and human
immunodeficiency virus infection: Clinicopathologic and virologic features of
114 patients from the Italian Cooperative Group on AIDS and tumors. J Clin Oncol
48. DeVita V, Hellman S, Rosenberg S: Cancer: Principles and Practice of
Oncology, 5th ed. Philadelphia, Lippincott and Raven, 1997.
49. Serrano M, Bellas C, Campo E, et al: Hodgkin’s disease in patients with
antibodies to human immunodeficiency virus: A study of 22 patients. Cancer
50. Errante D, Gabarre J, Fasan M, et al: Feasibility of the integration of
Stanford V chemotherapy regimen with highly active antiretroviral therapy and
G-CSF in patients with Hodgkin’s disease and HIV infection (abstract 37). Proc
Am Soc Clin Oncol 18:11a, 1999.
51. Horning SJ, Rosenberg SA, Hoppe RT: Brief chemotherapy (Stanford V) and
adjuvant radiotherapy for bulky or advanced Hodgkin’s disease: An update. Ann
Oncol 7(suppl 4):105-108, 1996.
52. Klencke B: Invasive anal disease and other non-AIDS defining neoplasms.
AIDS-Associated Malignancies: Biology and Clinical Management, San Francisco,
53. Petruckevitch A, Del Amo J, Phillips AN, et al: Risk of cancer in
patients with HIV disease. London African HIV/AIDS Study Group. Int J STD AIDS
54. Palefsky J: Anal squamous intraepithelial lesions in human
immunodeficiency virus-positive men and women. Semin Oncol 27:471-479, 2000.
55. Koblin BA, Hessol NA, Zauber AG, et al: Increased incidence of cancer
among homosexual men, New York City and San Francisco, 1978-1990. Am J Epidemiol
56. Lyter D, Kingsley L, Rinaldo C: Malignancies in the multicenter AIDS
cohort study (abstract 852). Proc Am Soc Clin Oncol 15:305, 1996.
57. Grulich AE, Wan X, Lau MG, et al: Risk of cancer in people with AIDS.
AIDS 13(7):839-843, 1999.
58. Palefsky JM, Holly EA, Ralston ML, et al: Prevalence and risk factors for
human papillomavirus infection of the anal canal in human immunodeficiency virus
(HIV)-positive and HIV-negative homosexual men. J Infect Dis 177(2):361-367,
59. Palefsky JM, Holly EA, Ralston ML, et al: High incidence of anal
high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative
homosexual and bisexual men. AIDS 12(5):495-503, 1998.
60. Palefsky JM: Anal squamous intraepithelial lesions: Relation to HIV and
human papillomavirus infection. J Acquir Immune Defic Syndr 21(suppl 1):S42-S48,
61. Sillman FH, Sedlis A: Anogenital papillomavirus infection and neoplasia
in immunodeficient women. Obstet Gynecol Clin North Am 14(2):537-558, 1987.
62. Hoffman R, Welton ML, Klencke B, et al: The significance of pretreatment
CD4 count on the outcome and treatment tolerance of HIV-positive patients with
anal cancer. Int J Radiat Oncol Biol Phys 44(1):127-131, 1999.
63. Appleby P, Beral V, Newton R, et al: Highly active antiretroviral therapy
and incidence of cancer in human immunodeficiency virus-infected adults. J Natl
Cancer Inst 92:1823-1830, 2000.
64. Jacobson LP, Yamashita TE, Detels R, et al: Impact of potent
antiretroviral therapy on the incidence of Kaposi’s sarcoma and non-Hodgkin’s
lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J
Acquir Immune Defic Syndr 21(suppl 1):S34-S41, 1999.
65. Buchbinder S: Combination antiretroviral therapy and incidence of
AIDS-related malignancies. J Acquir Immune Defic Syndr 21:S23-S26, 1999.
66. Ledergerber B, Telenti A, Egger M: Risk of HIV-related Kaposi’s sarcoma
and non-Hodgkin’s lymphoma with potent antiretroviral therapy: Prospective
cohort study. Br Med J 319:23-24, 1999.
67. Jones J, Hanson D, Dworkin M, et al: Effect of antiretroviral therapy on
recent trends in selected cancers among HIV-infected persons. J Acquir Immune
Defic Syndr 21: S11-S217, 1999.